URGN
UroGen Pharma Ltd.
$39.19
-0.32 (-0.81%)
At close · Jul 14
Market Cap
$1.91B
Shares
48,721,701
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$109.79M
+21.4%
FY2025
Net Income
-$153.49M
-21%
FY2025
Gross Margin
88.66%
-1.5pp
FY2025
Operating Margin
-113.73%
-6.7pp
FY2025
Operating Cash Flow
-$162.44M
-67.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $97M – $101M | $140.49M | $109.79M | $90.4M | $82.71M | $64.36M | $48.04M | $11.8M | $18K | $1.13M | $8.16M | |
| — | $14.26M | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M | $1.01M | $1.8M | $1.8M | $600K | |
| — | $126.24M | $97.34M | $81.52M | $73.35M | $56.7M | $42.89M | $10.79M | $18K | -$675K | $7.56M | |
| — | — | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% | 100% | -59.84% | 92.65% | |
| — | $62.83M | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M | $47.31M | $49.3M | — | — | |
| — | — | — | — | — | — | — | — | $60.2M | $39.57M | $8.81M | |
| — | $171.62M | $155.1M | $121.15M | $93.27M | $82.84M | $87.54M | $90.22M | — | — | — | |
| — | $310K | $307K | $329K | $802K | $924K | $831K | $400K | $300K | $400K | — | |
| — | — | — | — | — | — | — | — | $109.5M | $76.51M | — | |
| — | -$108.21M | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M | -$126.74M | -$109.48M | -$77.18M | -$19.95M | |
| — | — | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% | -1074.15% | -608211.11% | -6842.2% | -244.55% | |
| — | -$107.9M | -$124.56M | -$96.45M | -$64.73M | -$78.12M | -$91.46M | -$126.34M | -$109.18M | -$76.78M | — | |
| — | $4.69M | $5.97M | $8.9M | $2.64M | $938K | $365K | $1.99M | — | — | — | |
| — | -$903K | -$670K | -$229K | $838K | $72K | — | — | -$284K | — | — | |
| — | -$138.31M | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -$109.37M | -$125.11M | -$105.15M | -$75.53M | -$19.98M | |
| — | -$5.09M | $78K | $2.83M | $3.92M | $1.76M | $1.45M | $3.37M | $125K | $125K | $19K | |
| — | -$133.23M | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M | -$128.48M | -$105.15M | -$75.66M | -$20M | |
| — | — | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | -6707.18% | -245.16% | |
| — | — | — | — | — | — | — | -$128.48M | -$105.15M | -$75.66M | -$20.83M | |
| — | -$133.23M | -$153.53M | -$126.83M | -$102.13M | -$109.87M | -$111.12M | -$128.49M | -$104.87M | — | — | |
| USD/shares | — | — | -$3.19 | -$2.96 | -$3.55 | -$4.81 | — | — | — | — | — |
| shares | — | — | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M |
| shares | — | — | — | — | — | — | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.25×
EV/EBIT
—
Biotechnology median 25.44×
P/E (TTM)
—
Biotechnology median 7.40×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Jelmyto | $93,989,000 | $90,398,000 | $82,713,000 | $64,357,000 | $48,042,000 | $11,799,000 |
| Zusduri | $15,799,000 | $0 | — | — | — | — |